202 related articles for article (PubMed ID: 16460675)
1. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope.
Zhang J; Xu J; Li G; Dong D; Song X; Guo Q; Zhao J; Fu L; Chen W
Biochem Biophys Res Commun; 2006 Mar; 341(4):1164-71. PubMed ID: 16460675
[TBL] [Abstract][Full Text] [Related]
2. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen].
Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q
Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody.
Li G; Qu Y; Cai C; Kong Y; Liu S; Zhang J; Zhao J; Fu L; Xu J; Chen W
Biochem Biophys Res Commun; 2009 Aug; 385(4):591-5. PubMed ID: 19486894
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
5. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB
FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195
[TBL] [Abstract][Full Text] [Related]
7. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
Wu G; Feng C; Cao S; Guo A; Liu Z
Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
[TBL] [Abstract][Full Text] [Related]
8. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis.
Reed DS; Smoll J; Gibbs P; Little SF
Cytometry; 2002 Sep; 49(1):1-7. PubMed ID: 12210604
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro].
Belova EV; Dubileĭ SA; Kravchenko TB; Kolesnikov AV; Zakharova MIu; Shemiakin IG
Mol Gen Mikrobiol Virusol; 2004; (3):21-6. PubMed ID: 15354937
[TBL] [Abstract][Full Text] [Related]
10. Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
Wu G; Feng C; Hong Y; Guo A; Cao S; Dong J; Lin L; Liu Z
Appl Microbiol Biotechnol; 2010 Jun; 87(2):609-16. PubMed ID: 20213183
[TBL] [Abstract][Full Text] [Related]
11. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo.
Little SF; Webster WM; Fisher DE
FEMS Immunol Med Microbiol; 2011 Jun; 62(1):11-22. PubMed ID: 21231965
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.
Mechaly A; Levy H; Epstein E; Rosenfeld R; Marcus H; Ben-Arie E; Shafferman A; Ordentlich A; Mazor O
J Biol Chem; 2012 Sep; 287(39):32665-73. PubMed ID: 22869370
[TBL] [Abstract][Full Text] [Related]
14. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
15. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
16. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.
Abboud N; De Jesus M; Nakouzi A; Cordero RJ; Pujato M; Fiser A; Rivera J; Casadevall A
J Biol Chem; 2009 Sep; 284(37):25077-86. PubMed ID: 19617628
[TBL] [Abstract][Full Text] [Related]
17. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI
J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668
[TBL] [Abstract][Full Text] [Related]
18. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
Oscherwitz J; Yu F; Jacobs JL; Cease KB
Clin Vaccine Immunol; 2013 Mar; 20(3):341-9. PubMed ID: 23283638
[TBL] [Abstract][Full Text] [Related]
19. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.
Oscherwitz J; Yu F; Cease KB
Infect Immun; 2009 Dec; 77(12):5509-18. PubMed ID: 19805525
[TBL] [Abstract][Full Text] [Related]
20. Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine.
McComb RC; Ho CL; Bradley KA; Grill LK; Martchenko M
Vaccine; 2015 Nov; 33(48):6745-51. PubMed ID: 26514421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
